Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Cancer Sci Retrieve available abstracts of 159 articles: HTML format

Single Articles

April 2024
1. ALANAZI M, Weng T, McLeod L, Gearing LJ, et al
   Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
   Cancer Sci. 2024 Apr 9. doi: 10.1111/cas.16171.
   PubMed     Abstract available
   
   
   
2. MORISE M, Kato T, Matsumoto S, Inoue T, et al
   Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
   Cancer Sci. 2024;115:1296-1305.
   PubMed     Abstract available
   
   
   
3. MIZOTE Y, Inoue T, Akazawa T, Kunimasa K, et al
   Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.
   Cancer Sci. 2024;115:1114-1128.
   PubMed     Abstract available
   
   
   March 2024
4. 
   Correction to: Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
   Cancer Sci. 2024 Mar 20. doi: 10.1111/cas.16163.
   PubMed    
   
   
   
5. ISHIDA M, Iwasaku M, Doi T, Ishikawa T, et al
   Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
   Cancer Sci. 2024 Mar 7. doi: 10.1111/cas.16130.
   PubMed     Abstract available
   
   
   
6. WANG S, Wang J, Gong W, Zhang F, et al
   ILT4 facilitates angiogenesis in non-small cell lung cancer.
   Cancer Sci. 2024 Mar 3. doi: 10.1111/cas.16126.
   PubMed     Abstract available
   
   
   February 2024
7. KAJIWARA N, Kakihana M, Maeda J, Kaneko M, et al
   Salivary metabolomic biomarkers for non-invasive lung cancer detection.
   Cancer Sci. 2024 Feb 28. doi: 10.1111/cas.16112.
   PubMed     Abstract available
   
   
   
8. KAWAI S, Lin Y, Tsuge H, Ito H, et al
   Body mass index and lung cancer risk: Pooled analysis of 10 prospective cohort studies in Japan.
   Cancer Sci. 2024 Feb 4. doi: 10.1111/cas.16093.
   PubMed     Abstract available
   
   
   
9. YONEDA H, Mitsuhashi A, Yoshida A, Ogino H, et al
   Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.
   Cancer Sci. 2024;115:357-368.
   PubMed     Abstract available
   
   
   
10. HASEGAWA S, Shintani Y, Takuwa T, Aoe K, et al
    Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.
    Cancer Sci. 2024;115:507-528.
    PubMed     Abstract available
    
    
    January 2024
11. TSUJI K, Mizugaki H, Yokoo K, Kobayashi M, et al
    Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
    Cancer Sci. 2024 Jan 29. doi: 10.1111/cas.16094.
    PubMed     Abstract available
    
    
    
12. ZHANG J, Li Y, Yang Y, Huang J, et al
    A novel iTreg-related signature for prognostic prediction in lung adenocarcinoma.
    Cancer Sci. 2024;115:109-124.
    PubMed     Abstract available
    
    
    December 2023
13. SHIMOMURA Y, Sawa K, Imai T, Ihara Y, et al
    Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Cancer Sci. 2023 Dec 27. doi: 10.1111/cas.16056.
    PubMed     Abstract available
    
    
    
14. HUANG R, Wu D, Zhang K, Hu G, et al
    ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance.
    Cancer Sci. 2023 Dec 15. doi: 10.1111/cas.16052.
    PubMed     Abstract available
    
    
    
15. MITSUDOMI T, Ito H, Okada M, Sugawara S, et al
    Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
    Cancer Sci. 2023 Dec 14. doi: 10.1111/cas.16030.
    PubMed     Abstract available
    
    
    
16. 
    Correction to Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
    Cancer Sci. 2023 Dec 10. doi: 10.1111/cas.16000.
    PubMed    
    
    
    
17. SUMITOMO R, Menju T, Shimazu Y, Toyazaki T, et al
    M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor beta/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamou
    Cancer Sci. 2023;114:4521-4534.
    PubMed     Abstract available
    
    
    
18. WANG Q, Song X, Zhao F, Chen Q, et al
    Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA-based nomogram.
    Cancer Sci. 2023;114:4607-4621.
    PubMed     Abstract available
    
    
    November 2023
19. FUJIMOTO K, Matsumoto Y, Imabayashi T, Uchimura K, et al
    Suitability of respiratory endoscopy for sampling malignant thoracic tumors for comprehensive genomic profiling.
    Cancer Sci. 2023;114:4401-4412.
    PubMed     Abstract available
    
    
    
20. KANG N, Fan B, Sun Y, Xue P, et al
    Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis.
    Cancer Sci. 2023;114:4413-4425.
    PubMed     Abstract available
    
    
    October 2023
21. NAKANISHI T, Yoneshima Y, Okamura K, Yanagihara T, et al
    MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.
    Cancer Sci. 2023;114:4101-4113.
    PubMed     Abstract available
    
    
    September 2023
22. HUAI Q, Luo C, Song P, Bie F, et al
    Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
    Cancer Sci. 2023 Sep 20. doi: 10.1111/cas.15964.
    PubMed     Abstract available
    
    
    
23. ANDO C, Ichihara E, Nishi T, Morita A, et al
    Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
    Cancer Sci. 2023 Sep 15. doi: 10.1111/cas.15958.
    PubMed     Abstract available
    
    
    
24. HINOKUMA H, Kanamori Y, Ikeda K, Hao L, et al
    Distinct functions between ferrous and ferric iron in lung cancer cell growth.
    Cancer Sci. 2023 Sep 8. doi: 10.1111/cas.15949.
    PubMed     Abstract available
    
    
    
25. CHEN Y, Jin L, Ma Y, Liu Y, et al
    BACH1 promotes lung adenocarcinoma cell metastasis through transcriptional activation of ITGA2.
    Cancer Sci. 2023;114:3568-3582.
    PubMed     Abstract available
    
    
    August 2023
26. XIAO Y, Peng L, Xu Z, Tang Y, et al
    Association between adherence to Eat-Lancet diet and incidence and mortality of lung cancer: A prospective cohort study.
    Cancer Sci. 2023 Aug 31. doi: 10.1111/cas.15941.
    PubMed     Abstract available
    
    
    
27. KAGAWA Y, Nakai T, Taki T, Hashimoto H, et al
    Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma.
    Cancer Sci. 2023;114:3423-3432.
    PubMed     Abstract available
    
    
    July 2023
28. YOSHIDA T, Kumagai T, Toyozawa R, Katayama R, et al
    Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
    Cancer Sci. 2023 Jul 11. doi: 10.1111/cas.15888.
    PubMed     Abstract available
    
    
    
29. PARK SS, Kwon MR, Ju EJ, Shin SH, et al
    Targeting phosphomevalonate kinase enhances radiosensitivity via ubiquitination of the replication protein A1 in lung cancer cells.
    Cancer Sci. 2023 Jul 5. doi: 10.1111/cas.15896.
    PubMed     Abstract available
    
    
    
30. SHI Z, Weng J, Niu H, Yang H, et al
    D-1553: A novel KRAS(G12C) inhibitor with potent and selective cellular and in vivo antitumor activity.
    Cancer Sci. 2023;114:2951-2960.
    PubMed     Abstract available
    
    
    
31. GOU Q, Che S, Chen M, Chen H, et al
    PPARgamma inhibited tumor immune escape by inducing PD-L1 autophagic degradation.
    Cancer Sci. 2023;114:2871-2881.
    PubMed     Abstract available
    
    
    
32. ITO Y, Usui G, Seki M, Fukuyo M, et al
    Association of frequent hypermethylation with high grade histological subtype in lung adenocarcinoma.
    Cancer Sci. 2023;114:3003-3013.
    PubMed     Abstract available
    
    
    
33. KITAMURA Y, Zha L, Liu R, Shima M, et al
    Association of mesothelioma deaths with neighborhood asbestos exposure due to a large-scale asbestos-cement plant.
    Cancer Sci. 2023;114:2973-2985.
    PubMed     Abstract available
    
    
    June 2023
34. GOTO Y, Shukuya T, Murata A, Kikkawa H, et al
    Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
    Cancer Sci. 2023;114:2560-2568.
    PubMed     Abstract available
    
    
    
35. QIN Y, Long Y, Tang Y, Tian Y, et al
    Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study.
    Cancer Sci. 2023;114:2552-2559.
    PubMed     Abstract available
    
    
    
36. HORIE M, Tanaka H, Suzuki M, Sato Y, et al
    An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma.
    Cancer Sci. 2023;114:2596-2608.
    PubMed     Abstract available
    
    
    May 2023
37. SUGAWARA S, Tanaka K, Imamura F, Yamamoto N, et al
    Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
    Cancer Sci. 2023 May 15. doi: 10.1111/cas.15816.
    PubMed     Abstract available
    
    
    
38. FUJITA K, Arai R, Shoji S, Saito R, et al
    Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine a trial.
    Cancer Sci. 2023 May 3. doi: 10.1111/cas.15831.
    PubMed     Abstract available
    
    
    
39. FUJIWARA Y, Makihara R, Hase T, Hashimoto N, et al
    Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
    Cancer Sci. 2023;114:2087-2097.
    PubMed     Abstract available
    
    
    
40. RAO X, Xing B, Wu Z, Bin Y, et al
    Targeting polymerase theta impairs tumorigenesis and enhances radiosensitivity in lung adenocarcinoma.
    Cancer Sci. 2023;114:1943-1957.
    PubMed     Abstract available
    
    
    
41. KONISHI Y, Taki T, Nakai T, Kuroe T, et al
    Clinicopathological features and prognostic impact of dirty necrosis in metastatic lung cancers from the colon and rectum.
    Cancer Sci. 2023;114:2169-2177.
    PubMed     Abstract available
    
    
    April 2023
42. CHEN MC, Hung MY, Pan CM, Huang SW, et al
    Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer.
    Cancer Sci. 2023 Apr 5. doi: 10.1111/cas.15806.
    PubMed     Abstract available
    
    
    
43. LIAO J, Lai H, Liu C, Zhang X, et al
    Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.
    Cancer Sci. 2023 Apr 4. doi: 10.1111/cas.15804.
    PubMed     Abstract available
    
    
    
44. LUO Y, Akatsuka S, Motooka Y, Kong Y, et al
    BRCA1 haploinsufficiency impairs iron metabolism to promote chrysotile-induced mesothelioma via ferroptosis resistance.
    Cancer Sci. 2023;114:1423-1436.
    PubMed     Abstract available
    
    
    
45. MATSUBARA D, Yoshimoto T, Akolekar N, Totsuka T, et al
    Genetic and phenotypic determinants of morphologies in 3D cultures and xenografts of lung tumor cell lines.
    Cancer Sci. 2023;114:1757-1770.
    PubMed     Abstract available
    
    
    March 2023
46. SHIBAHARA D, Akanuma N, Kobayashi IS, Heo E, et al
    TIP60 is required for tumorigenesis in non-small cell lung cancer.
    Cancer Sci. 2023 Mar 14. doi: 10.1111/cas.15785.
    PubMed     Abstract available
    
    
    
47. HAN R, Zhang Y, Wang T, Xiao H, et al
    Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
    Cancer Sci. 2023 Mar 7. doi: 10.1111/cas.15778.
    PubMed     Abstract available
    
    
    
48. NAKAMURA T, Sato A, Nakashima C, Abe T, et al
    Absence of copy number gain of EGFR: A possible predictive marker of long-term response to afatinib.
    Cancer Sci. 2023;114:1045-1055.
    PubMed     Abstract available
    
    
    
49. OKAMURA K, Inoue H, Tanaka K, Ikematsu Y, et al
    Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma.
    Cancer Sci. 2023;114:1095-1107.
    PubMed     Abstract available
    
    
    February 2023
50. ZHAO L, Wu X, Zhang Z, Fang L, et al
    ELF1 suppresses autophagy to reduce cisplatin resistance via miR-152-3p/NCAM1/ERK axis in lung cancer cells.
    Cancer Sci. 2023 Feb 27. doi: 10.1111/cas.15770.
    PubMed     Abstract available
    
    
    
51. LI Z, Chen S, He X, Gong S, et al
    SLC3A2 Promotes Tumor Associated Macrophage Polarization via Metabolic Reprogramming in Lung Cancer.
    Cancer Sci. 2023 Feb 15. doi: 10.1111/cas.15760.
    PubMed     Abstract available
    
    
    
52. TAKAHASHI T, Nishio M, Nishino K, Yoshiki Y, et al
    Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.
    Cancer Sci. 2023 Feb 8. doi: 10.1111/cas.15752.
    PubMed     Abstract available
    
    
    
53. NGUYEN NT, Mitsuhashi A, Ogino H, Kozai H, et al
    S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor.
    Cancer Sci. 2023;114:384-398.
    PubMed     Abstract available
    
    
    
54. OGUCHI K, Araki H, Tsuji S, Nakamura M, et al
    TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
    Cancer Sci. 2023;114:654-664.
    PubMed     Abstract available
    
    
    
55. IMAI K, Nanjo H, Shigeeda W, Sugai T, et al
    Intraoperative rapid immunohistochemistry with noncontact antibody mixing for undiagnosed pulmonary tumors.
    Cancer Sci. 2023;114:702-711.
    PubMed     Abstract available
    
    
    
56. WANG H, Wu S, Li Z, Zhang C, et al
    Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.
    Cancer Sci. 2023;114:665-679.
    PubMed     Abstract available
    
    
    
57. YOSHIMURA A, Yamada T, Serizawa M, Uehara H, et al
    High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
    Cancer Sci. 2023;114:606-618.
    PubMed     Abstract available
    
    
    January 2023
58. LI K, Mao S, Li X, Zhao H, et al
    Frizzled-7-targeting Antibody (SHH002-hu1) Potently Suppresses Non-small Cell Lung Cancer via Wnt/beta-catenin signaling.
    Cancer Sci. 2023 Jan 10. doi: 10.1111/cas.15721.
    PubMed     Abstract available
    
    
    
59. FUNATO Y, Hashizume O, Miki H
    Phosphatase-independent role of phosphatase of regenerating liver in cancer progression.
    Cancer Sci. 2023;114:25-33.
    PubMed     Abstract available
    
    
    
60. MINNAI F, Noci S, Chierici M, Cotroneo CE, et al
    Genetic predisposition to lung adenocarcinoma outcome is a feature already present in patients' noninvolved lung tissue.
    Cancer Sci. 2023;114:281-294.
    PubMed     Abstract available
    
    
    
61. ZHENG JQ, Lin CH, Lee HH, Chang WM, et al
    AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
    Cancer Sci. 2023;114:306-320.
    PubMed     Abstract available
    
    
    
62. IWASA S, Koyama T, Nishino M, Kondo S, et al
    First-in-human study of ONO-4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors.
    Cancer Sci. 2023;114:211-220.
    PubMed     Abstract available
    
    
    
63. SORA S, Sukhbaatar A, Fukushige S, Mori S, et al
    Combination therapy of lymphatic drug delivery and total body irradiation in a metastatic lymph node and lung mouse model.
    Cancer Sci. 2023;114:227-235.
    PubMed     Abstract available
    
    
    December 2022
64. SHIIYA A, Noguchi T, Tomaru U, Ariga S, et al
    EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.
    Cancer Sci. 2022 Dec 18. doi: 10.1111/cas.15701.
    PubMed     Abstract available
    
    
    
65. LI M, Zhang J, Meng X, Liu B, et al
    Limb expression 1-like protein promotes epithelial-mesenchymal transition and epidermal growth factor receptor-tyrosine kinase inhibitor resistance via nucleolin-mediated ribosomal RNA synthesis in non-small cell lung cancer.
    Cancer Sci. 2022 Dec 7. doi: 10.1111/cas.15687.
    PubMed     Abstract available
    
    
    
66. YANG L, Zhang Q, Xiong Y, Dang Z, et al
    A Subset of VEGFR-TKIs Activates AMPK in LKB1-mutant Lung Cancer.
    Cancer Sci. 2022 Dec 2. doi: 10.1111/cas.15677.
    PubMed     Abstract available
    
    
    
67. LIU M, Zhou Z, Liu F, Wang M, et al
    CT and CEA-based machine learning model for predicting malignant pulmonary nodules.
    Cancer Sci. 2022;113:4363-4373.
    PubMed     Abstract available
    
    
    
68. ZHAN F, Deng Q, Chen Z, Xie C, et al
    SAR1A regulates the RhoA/YAP and autophagy signaling pathways to influence osteosarcoma invasion and metastasis.
    Cancer Sci. 2022;113:4104-4119.
    PubMed     Abstract available
    
    
    November 2022
69. TAKAHASHI H, Sakakibara-Konishi J, Furuta M, Shoji T, et al
    Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small cell lung cancer.
    Cancer Sci. 2022 Nov 21. doi: 10.1111/cas.15674.
    PubMed     Abstract available
    
    
    
70. KAWAGUCHI Y, Ohshio Y, Watanabe A, Shiratori T, et al
    Depletion of tumor-associated macrophages inhibits the lung cancer growth and enhances the antitumor effect of cisplatin.
    Cancer Sci. 2022 Nov 21. doi: 10.1111/cas.15671.
    PubMed     Abstract available
    
    
    
71. ZHANG LX, Yang X, Wu ZB, Liao ZM, et al
    TTI1 promotes non-small cell lung cancer progression by regulating the mTOR signaling pathway.
    Cancer Sci. 2022 Nov 20. doi: 10.1111/cas.15668.
    PubMed     Abstract available
    
    
    
72. LIANG S, Wang Q, Wen Y, Wang Y, et al
    Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation.
    Cancer Sci. 2022 Nov 14. doi: 10.1111/cas.15653.
    PubMed     Abstract available
    
    
    
73. TANIYAMA Y, Oze I, Koyanagi YN, Kawakatsu Y, et al
    Changes in survival of patients with non-small cell lung cancer in Japan: an interrupted time series study.
    Cancer Sci. 2022 Nov 11. doi: 10.1111/cas.15646.
    PubMed     Abstract available
    
    
    
74. ZHU Y, Yang Y, Bu H, Huang H, et al
    Apelin-mediated deamidation of HMGA1 promotes tumorigenesis by enhancing SREBP1 activity and lipid synthesis.
    Cancer Sci. 2022;113:3722-3734.
    PubMed     Abstract available
    
    
    
75. OCHIAI R, Hayashi K, Yamamoto H, Fujii R, et al
    Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment.
    Cancer Sci. 2022;113:3960-3971.
    PubMed     Abstract available
    
    
    
76. HUANG Y, Zheng Y, Yao L, Qiao F, et al
    RNA binding protein POP7 regulates ILF3 mRNA stability and expression to promote breast cancer progression.
    Cancer Sci. 2022;113:3801-3813.
    PubMed     Abstract available
    
    
    October 2022
77. LI J, Liu K, Ji Z, Wang Y, et al
    Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
    Cancer Sci. 2022 Oct 30. doi: 10.1111/cas.15629.
    PubMed     Abstract available
    
    
    
78. NODA-NARITA S, Naito T, Udagawa H, Goto K, et al
    Nivolumab-induced radiation recall pneumonitis in non-small cell lung cancer patients with thoracic radiation therapy.
    Cancer Sci. 2022 Oct 26. doi: 10.1111/cas.15621.
    PubMed     Abstract available
    
    
    
79. YAMAZOE M, Ozasa H, Tsuji T, Funazo T, et al
    YAP1 mediates initial cell survival during lorlatinib treatment via AKT signaling in ROS1-rearranged lung cancer.
    Cancer Sci. 2022 Oct 26. doi: 10.1111/cas.15622.
    PubMed     Abstract available
    
    
    
80. SUN X, Wang X, Yan C, Zheng S, et al
    Tumor cell-released LC3-positive EVs promote lung metastasis of breast cancer through enhancing premetastatic niche formation.
    Cancer Sci. 2022;113:3405-3416.
    PubMed     Abstract available
    
    
    
81. OCHI K, Suzawa K, Thu YM, Takatsu F, et al
    Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast.
    Cancer Sci. 2022;113:3428-3436.
    PubMed     Abstract available
    
    
    September 2022
82. XU X, Zhang P, Huang Y, Shi W, et al
    METTL3 mediated m(6) A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small cell lung cancer.
    Cancer Sci. 2022 Sep 17. doi: 10.1111/cas.15590.
    PubMed     Abstract available
    
    
    
83. TANIGUCHI H, Akagi K, Dotsu Y, Yamada T, et al
    Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
    Cancer Sci. 2022 Sep 10. doi: 10.1111/cas.15579.
    PubMed     Abstract available
    
    
    
84. SOMEYA M, Tokita S, Kanaseki T, Kitagawa M, et al
    Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer.
    Cancer Sci. 2022 Sep 7. doi: 10.1111/cas.15566.
    PubMed     Abstract available
    
    
    
85. KENMOTSU H, Sugawara S, Watanabe Y, Saito H, et al
    Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).
    Cancer Sci. 2022 Sep 5. doi: 10.1111/cas.15564.
    PubMed     Abstract available
    
    
    
86. LUO Y, Zhang Z, Zheng B, Wu P, et al
    Comprehensive analyses of m(6) A-related lncRNA profiles with prognosis, chemotherapy response, and immune landscape in SCLC.
    Cancer Sci. 2022 Sep 1. doi: 10.1111/cas.15553.
    PubMed     Abstract available
    
    
    
87. SAITO Y, Fujiwara Y, Shinchi Y, Mito R, et al
    Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis.
    Cancer Sci. 2022;113:3255-3266.
    PubMed     Abstract available
    
    
    August 2022
88. SAKASHITA T, Yanagitani N, Koike S, Low SK, et al
    Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
    Cancer Sci. 2022 Aug 11. doi: 10.1111/cas.15529.
    PubMed     Abstract available
    
    
    July 2022
89. NISHIO S, Yonemori K, Usami T, Minobe S, et al
    Pembrolizumab Plus Chemotherapy in Japanese Patients With Persistent, Recurrent or Metastatic Cervical Cancer: Results From KEYNOTE-826.
    Cancer Sci. 2022 Jul 6. doi: 10.1111/cas.15479.
    PubMed     Abstract available
    
    
    
90. MIYAKAWA K, Miyashita N, Horie M, Terasaki Y, et al
    ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
    Cancer Sci. 2022 Jul 5. doi: 10.1111/cas.15481.
    PubMed     Abstract available
    
    
    June 2022
91. NAKAHAMA K, Kaneda H, Osawa M, Fukui M, et al
    Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer.
    Cancer Sci. 2022 Jun 20. doi: 10.1111/cas.15464.
    PubMed     Abstract available
    
    
    
92. ZHANG S, He Y, Xuan Q, Ling X, et al
    TMEM139 prevents NSCLC metastasis by inhibiting lysosomal degradation of E-cadherin.
    Cancer Sci. 2022;113:1999-2007.
    PubMed     Abstract available
    
    
    May 2022
93. YAMAMOTO N, Kamitani T, Kanda K, Ito Y, et al
    Real-world Outcomes of Pembrolizumab Monotherapy in Non-Small Cell Lung Cancer in Japan: a Post-marketing Surveillance.
    Cancer Sci. 2022 May 24. doi: 10.1111/cas.15439.
    PubMed     Abstract available
    
    
    April 2022
94. IKEZAWA Y, Mizugaki H, Morita R, Tateishi K, et al
    Current status of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression.
    Cancer Sci. 2022 Apr 4. doi: 10.1111/cas.15361.
    PubMed     Abstract available
    
    
    
95. NIIMI T, Nakai T, Aokage K, Tane K, et al
    Prognostic impact of count of extratumoral lymphatic permeation in lung adenocarcinoma and its relation to the immune microenvironment.
    Cancer Sci. 2022;113:1497-1506.
    PubMed     Abstract available
    
    
    
96. YANG X, Chen R, Chen Y, Zhou Y, et al
    Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1-IL-8 signaling-mediated epithelial-mesenchymal transition in lung adenocarcinoma.
    Cancer Sci. 2022;113:1195-1207.
    PubMed     Abstract available
    
    
    
97. GU J, Qi Y, Lu Y, Tao Q, et al
    Lung adenocarcinoma-derived vWF promotes tumor metastasis by regulating PHKG1-mediated glycogen metabolism.
    Cancer Sci. 2022;113:1362-1376.
    PubMed     Abstract available
    
    
    
98. SAITOU A, Hasegawa Y, Fujitani N, Ariki S, et al
    N-glycosylation regulates MET processing and signaling.
    Cancer Sci. 2022;113:1292-1304.
    PubMed     Abstract available
    
    
    
99. NOMURA K, Nakai T, Nishina Y, Sakamoto N, et al
    18F-fluorodeoxyglucose uptake in PET is associated with the tumor microenvironment in metastatic lymph nodes and prognosis in N2 lung adenocarcinoma.
    Cancer Sci. 2022;113:1488-1496.
    PubMed     Abstract available
    
    
    March 2022
100. WANG X, Huang R, Lu Z, Wang Z, et al
     Exosomes from M1-polarized macrophages promote apoptosis in lung adenocarcinoma via the miR-181a-5p/ETS1/STK16 axis.
     Cancer Sci. 2022;113:986-1001.
     PubMed     Abstract available
     
     
     
101. ZHANG W, Li Y, Lyu J, Shi F, et al
     An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
     Cancer Sci. 2022;113:891-903.
     PubMed     Abstract available
     
     
     
102. WANG H, Xia L, Yao CC, Dong H, et al
     NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.
     Cancer Sci. 2022;113:838-851.
     PubMed     Abstract available
     
     
     
103. NORO R, Honda K, Nagashima K, Motoi N, et al
     Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas.
     Cancer Sci. 2022;113:1002-1009.
     PubMed     Abstract available
     
     
     February 2022
104. TSUJI K, Kida Y, Koshikawa N, Yamamoto S, et al
     Suppression of non-small-cell lung cancer A549 tumor growth by an mtDNA mutation-targeting pyrrole-imidazole polyamide-triphenylphosphonium and a senolytic drug.
     Cancer Sci. 2022 Feb 2. doi: 10.1111/cas.15290.
     PubMed     Abstract available
     
     
     
105. LIU Y, Lai M, Li S, Wang Y, et al
     LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
     Cancer Sci. 2022;113:709-720.
     PubMed     Abstract available
     
     
     
106. GAO S, Guo W, Liu T, Liang N, et al
     Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma.
     Cancer Sci. 2022;113:648-659.
     PubMed     Abstract available
     
     
     
107. CHAI RC, Liu X, Pang B, Liu YQ, et al
     Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.
     Cancer Sci. 2022;113:796-801.
     PubMed     Abstract available
     
     
     January 2022
108. KOGA T, Suda K, Mitsudomi T
     Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
     Cancer Sci. 2022 Jan 7. doi: 10.1111/cas.15263.
     PubMed     Abstract available
     
     
     
109. LIAO WC, Lin TJ, Liu YC, Wei YS, et al
     Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1-STAT1 loop in lung adenocarcinoma.
     Cancer Sci. 2022;113:205-220.
     PubMed     Abstract available
     
     
     
110. NIU X, Wang W, Liang T, Li S, et al
     CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.
     Cancer Sci. 2022;113:28-40.
     PubMed     Abstract available
     
     
     
111. SUMIYA R, Terayama M, Hagiwara T, Nakata K, et al
     Loss of GSTO2 contributes to cell growth and mitochondria function via the p38 signaling in lung squamous cell carcinoma.
     Cancer Sci. 2022;113:195-204.
     PubMed     Abstract available
     
     
     
112. LIU S, Jiang Z, Xiao P, Li X, et al
     Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
     Cancer Sci. 2022;113:79-90.
     PubMed     Abstract available
     
     
     December 2021
113. KANAYAMA M, Kuwata T, Mori M, Nemoto Y, et al
     Prognostic impact of circulating tumor cells detected with the microfluidic "Universal CTC-chip" for primary lung cancer.
     Cancer Sci. 2021 Dec 29. doi: 10.1111/cas.15255.
     PubMed     Abstract available
     
     
     
114. MITSUHASHI A, Kondoh K, Horikawa K, Koyama K, et al
     Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker.
     Cancer Sci. 2021;112:4853-4866.
     PubMed     Abstract available
     
     
     
115. HONG J, Shiba-Ishii A, Kim Y, Noguchi M, et al
     Ovarian carcinoma immunoreactive antigen domain 2 controls mitochondrial apoptosis in lung adenocarcinoma.
     Cancer Sci. 2021;112:5114-5126.
     PubMed     Abstract available
     
     
     November 2021
116. OKAZAKI S, Shibuya K, Takura T, Miyasaka Y, et al
     Cost-Effectiveness of Carbon-Ion Radiotherapy versus Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer.
     Cancer Sci. 2021 Nov 25. doi: 10.1111/cas.15216.
     PubMed     Abstract available
     
     
     
117. YU H, Wang H, Qie A, Wang J, et al
     FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect.
     Cancer Sci. 2021;112:4655-4668.
     PubMed     Abstract available
     
     
     October 2021
118. YUN HS, Lee J, Kim JY, Sim YJ, et al
     A novel function of HRP-3 in regulating cell cycle progression via the HDAC-E2F1-Cyclin E pathway in lung cancer.
     Cancer Sci. 2021 Oct 29. doi: 10.1111/cas.15183.
     PubMed     Abstract available
     
     
     
119. SAKATA S, Otsubo K, Yoshida H, Ito K, et al
     Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small cell lung cancer: WJOG13019L.
     Cancer Sci. 2021 Oct 26. doi: 10.1111/cas.15176.
     PubMed     Abstract available
     
     
     
120. TAKAHASHI T, Sakai K, Kenmotsu H, Yoh K, et al
     Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
     Cancer Sci. 2021 Oct 24. doi: 10.1111/cas.15171.
     PubMed     Abstract available
     
     
     
121. NGUYEN YTM, Fujisawa M, Nguyen TB, Suehara Y, et al
     Tet2-deficency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model.
     Cancer Sci. 2021 Oct 17. doi: 10.1111/cas.15165.
     PubMed     Abstract available
     
     
     
122. LIU C, Zhang W, Wang J, Si T, et al
     Tumor-associated macrophage-derived transforming growth factor-beta promotes colorectal cancer progression through HIF1-TRIB3 signaling.
     Cancer Sci. 2021;112:4198-4207.
     PubMed     Abstract available
     
     
     
123. GUO K, Wang P, Zhang L, Zhou Y, et al
     Transcription factor POU4F2 promotes colorectal cancer cell migration and invasion through hedgehog-mediated epithelial-mesenchymal transition.
     Cancer Sci. 2021;112:4176-4186.
     PubMed     Abstract available
     
     
     
124. HASEGAWA N, Kohsaka S, Kurokawa K, Shinno Y, et al
     Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
     Cancer Sci. 2021;112:4393-4403.
     PubMed     Abstract available
     
     
     September 2021
125. SATOUCHI M, Nosaki K, Takahashi T, Nakagawa K, et al
     First-Line Pembrolizumab Versus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-024 Japan Subset.
     Cancer Sci. 2021 Sep 20. doi: 10.1111/cas.15144.
     PubMed     Abstract available
     
     
     
126. QI J, Hong B, Tao R, Sun R, et al
     Prediction model for malignant pulmonary nodules based on cfMeDIP-seq and machine learning.
     Cancer Sci. 2021;112:3918-3923.
     PubMed     Abstract available
     
     
     
127. CHEN J, Song Y, Miao F, Chen G, et al
     PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8(+) T cell exhaustion during metastasis.
     Cancer Sci. 2021;112:3437-3454.
     PubMed     Abstract available
     
     
     
128. TAKAHASHI K, Tanabe R, Ehata S, Kubota SI, et al
     Visualization of the cancer cell cycle by tissue-clearing technology using the Fucci reporter system.
     Cancer Sci. 2021;112:3796-3809.
     PubMed     Abstract available
     
     
     
129. YIMING R, Takeuchi Y, Nishimura T, Li M, et al
     MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
     Cancer Sci. 2021;112:3810-3821.
     PubMed     Abstract available
     
     
     
130. OKUDELA K, Matsumura M, Arai H, Woo T, et al
     The nonsmokers' and smokers' pathways in lung adenocarcinoma: Histological progression and molecular bases.
     Cancer Sci. 2021;112:3411-3418.
     PubMed     Abstract available
     
     
     
131. KODAMA Y, Tanaka I, Sato T, Hori K, et al
     Oxytocin receptor is a promising therapeutic target of malignant mesothelioma.
     Cancer Sci. 2021;112:3520-3532.
     PubMed     Abstract available
     
     
     August 2021
132. YAMAMOTO N, Nakanishi Y, Gemma A, Nakagawa K, et al
     Real-world safety of nivolumab in patients with non-small cell lung cancer in Japan: postmarketing surveillance.
     Cancer Sci. 2021 Aug 25. doi: 10.1111/cas.15117.
     PubMed     Abstract available
     
     
     
133. XU F, Hua Q, Zhang A, Zhang D, et al
     LncRNA AC020978 facilitates non-small cell lung cancer progression by interacting with MDH2 and activating AKT pathway.
     Cancer Sci. 2021 Aug 23. doi: 10.1111/cas.15116.
     PubMed     Abstract available
     
     
     
134. YU X, Yan J, Chen X, Wei J, et al
     Identification of a peptide binding to cancer antigen Kita-kyushu lung cancer antigen 1 from a phage-displayed library.
     Cancer Sci. 2021 Aug 12. doi: 10.1111/cas.15109.
     PubMed     Abstract available
     
     
     
135. ZHANG Y, Li J, Wang B, Chen T, et al
     LDH-A negatively regulates dMMR in colorectal cancer.
     Cancer Sci. 2021;112:3050-3063.
     PubMed     Abstract available
     
     
     
136. WANG Y, Chen D, Liu Y, Zhang Y, et al
     AQP3-mediated H2 O2 uptake inhibits LUAD autophagy by inactivating PTEN.
     Cancer Sci. 2021;112:3278-3292.
     PubMed     Abstract available
     
     
     
137. MORI K, Higurashi M, Ishikawa F, Shibanuma M, et al
     Rac1-mediated sustained beta4 integrin level develops reattachment ability of breast cancer cells after anchorage loss.
     Cancer Sci. 2021;112:3205-3217.
     PubMed     Abstract available
     
     
     
138. LIU L, Yan H, Ruan M, Yang H, et al
     An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
     Cancer Sci. 2021;112:3083-3098.
     PubMed     Abstract available
     
     
     
139. ZHANG C, Wang J, Sun Z, Cao Y, et al
     Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
     Cancer Sci. 2021;112:3005-3017.
     PubMed     Abstract available
     
     
     
140. TOMITA T, Kato M, Hiratsuka S
     Regulation of vascular permeability in cancer metastasis.
     Cancer Sci. 2021;112:2966-2974.
     PubMed     Abstract available
     
     
     July 2021
141. SHI H, Niimi A, Takeuchi T, Shiogama K, et al
     CEBPgamma facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation.
     Cancer Sci. 2021;112:2770-2780.
     PubMed     Abstract available
     
     
     June 2021
142. FUKUDA K, Otani S, Takeuchi S, Arai S, et al
     Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
     Cancer Sci. 2021 Jun 19. doi: 10.1111/cas.15035.
     PubMed     Abstract available
     
     
     
143. HE DH, Chen YF, Zhou YL, Zhang SB, et al
     Phytochemical library screen reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
     Cancer Sci. 2021 Jun 3. doi: 10.1111/cas.15005.
     PubMed     Abstract available
     
     
     
144. ARIYASU R, Uchibori K, Sasaki T, Tsukahara M, et al
     Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
     Cancer Sci. 2021;112:2371-2380.
     PubMed     Abstract available
     
     
     
145. WANG H, Jiang X, Cheng Y, Ren H, et al
     MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain.
     Cancer Sci. 2021;112:2210-2222.
     PubMed     Abstract available
     
     
     May 2021
146. SHUAI S, Liao X, Wang H, Liu L, et al
     TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small cell lung cancer.
     Cancer Sci. 2021 May 31. doi: 10.1111/cas.15000.
     PubMed     Abstract available
     
     
     
147. TORIYAMA K, Takano N, Kokuba H, Kazama H, et al
     Azithromycin enhances the cytotoxicity of DNA-damaging drugs via lysosomal membrane permeabilization in lung cancer cells.
     Cancer Sci. 2021 May 29. doi: 10.1111/cas.14992.
     PubMed     Abstract available
     
     
     
148. HORINOUCHI H, Nogami N, Saka H, Nishio M, et al
     Pembrolizumab Plus Pemetrexed-Platinum for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: KEYNOTE-189 Japan Study.
     Cancer Sci. 2021 May 25. doi: 10.1111/cas.14980.
     PubMed     Abstract available
     
     
     
149. HAN CL, Chen XR, Lan A, Hsu YL, et al
     N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.
     Cancer Sci. 2021;112:1911-1923.
     PubMed     Abstract available
     
     
     
150. LU S, Sun Z, Hu W, Yin S, et al
     PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B.
     Cancer Sci. 2021;112:1878-1887.
     PubMed     Abstract available
     
     
     
151. NISHIYA N, Oku Y, Ishikawa C, Fukuda T, et al
     Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.
     Cancer Sci. 2021;112:1963-1974.
     PubMed     Abstract available
     
     
     
152. NAKAMURA IT, Ikegami M, Hasegawa N, Hayashi T, et al
     Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.
     Cancer Sci. 2021;112:2006-2019.
     PubMed     Abstract available
     
     
     
153. WATANABE H, Ichihara E, Kayatani H, Makimoto G, et al
     VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
     Cancer Sci. 2021;112:1853-1864.
     PubMed     Abstract available
     
     
     
154. SHINTANI Y, Okami J, Ito H, Ohtsuka T, et al
     Clinical features and outcomes of patients with stage I multiple primary lung cancers.
     Cancer Sci. 2021;112:1924-1935.
     PubMed     Abstract available
     
     
     
155. WANG S, Cai J, Zhang S, Dong M, et al
     Loss of polarity protein Par3, via transcription factor Snail, promotes bladder cancer metastasis.
     Cancer Sci. 2021 May 1. doi: 10.1111/cas.14920.
     PubMed     Abstract available
     
     
     April 2021
156. FUJIMOTO M, Kamiyama M, Fuse K, Ryuno H, et al
     ASK1 suppresses NK cell-mediated intravascular tumor cell clearance in lung metastasis.
     Cancer Sci. 2021;112:1633-1643.
     PubMed     Abstract available
     
     
     
157. ISOMURA H, Taguchi A, Kajino T, Asai N, et al
     Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1alpha regulator.
     Cancer Sci. 2021;112:1614-1623.
     PubMed     Abstract available
     
     
     
158. SETO T, Ohashi K, Sugawara S, Nishio M, et al
     Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
     Cancer Sci. 2021;112:1556-1566.
     PubMed     Abstract available
     
     
     
159. NISHIO M, Saito H, Goto K, Watanabe S, et al
     IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.
     Cancer Sci. 2021;112:1534-1544.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.